Search results
Results from the WOW.Com Content Network
January 30, 2024. 0. Patients who have immune-related adverse events when treated for non–small cell lung cancer (NSCLC) may live longer than those without these complications, according to a ...
Key studies on non–small cell lung cancer presented at ESMO 2023 include strong practice-changing results from the PAPILLON, LIBRETTO, and MARIPOSA trials, as discussed by Dr Enriqueta Felipe.
Lung Cancer : Review in-depth clinical information, latest medical news, and guidelines on lung cancer, specifically small-cell lung cancer and non-small-cell lung cancer. Read the latest ...
Is Consolidation Osimertinib Superior to Durvalumab in EGFR-Mutated Non–Small Cell Lung Cancer? Immune-Related Adverse Events Linked to Longer Survival in Patients With Non-Small Cell Lung ...
Radiation dose to the left and right pulmonary veins was significantly associated with incident AF. Dose volumes most strongly associated with AF were ≥ 55 Gy (V55) on the left and ≥ 10 Gy ...
January 04, 2024. 0. Dr Narjust Florez explores the transformative shifts in the treatment landscape for early-stage non–small cell lung cancer over the years, particularly emphasizing the ...
Practice-changing studies in advanced non-small cell lung cancer presented at ASCO 2024 are reviewed by Dr Ticiana Leal, including the phase 3 LAURA and PALOMA-3 studies and a 5-year update of CROWN.
The investigational PD-1/VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced PD-L1-positive NSCLC.
EGFR, located at chromosome 7p12, spans approximately 200 kb and contains 28 exons. It is a member of the ErbB family of four closely related TK receptors: EGFR (ErbB1), HER2/c-neu (ErbB2), HER3 ...
A meta-analysis confirms that neoadjuvant chemoimmunotherapy improves survival outcomes in most patients with resectable NSCLC, except for overall survival in patients with baseline PD-L1 below 1%.